Latest Blog: 9th January 2020
The Future of Cell and Gene Therapy Manufacturing Just Got Brighter – Our investment in OriBiotech
Advances in cell and gene therapies (CGT) offer the potential to transform medicine. They create an inflection point in the ability to treat and potentially cure many intractable illnesses. Since Novartis broke open the market in 2017 with Kymriah, followed a few months later by Gilead’s Yescarta, scientific development of CGT is booming [...]